Cognition Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

Cognition Therapeutics

04/08/2025 14:46

Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Cognition Therapeutics Inc is for a loss of 11 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 80.9% above its last closing price of $0.67

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.11
-0.11
-0.14
Missed
-27
Dec. 31 2025
-0.15
-0.14
-0.17
Missed
-19.7
Sep. 30 2024
-0.18
-0.22
-0.25
Missed
-11.1​
Jun. 30 2024
-0.22
-0.24
-0.18
Beat
23.7
​​Mar. 31 2024
-0.25
-0.25
-0.27
Missed
-9.5
Dec. 31 2023
-0.34
-0.27
Beat
21.1​
Sep. 30 2023
-0.20
-0.24
-0.22
Beat
6.9
Jun. 30 2023
-0.15
-0.19
-0.16
Beat
15.3

This summary was machine generated August 4 at 13:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)